Clinical Research Directory
Browse clinical research sites, groups, and studies.
30 clinical studies listed.
Filters:
Tundra lists 30 Cannabis clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT04810858
Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury
This study applies a hypothesis-driven approach to examine the effects of chronic marijuana use on HIV-associated inflammation and its subsequent impacts on central nervous system function, with the goal of identifying the mechanisms through which cannabinoids modulate neurological disorders and other comorbidities in persons with HIV.
Gender: All
Ages: 25 Years - 59 Years
Updated: 2026-03-31
1 state
NCT04325958
Age Differences in the Effects of Cannabis on Simulated Driving
Epidemiological studies suggest that the use of cannabis is associated with an increase in the risk of motor vehicle collisions. It is also known that younger users may be at increased risk for motor vehicle collisions. Further, the frequency with which cannabis is used may be an important variable in determining the effects of cannabis on driving. The purpose of the present study will be to investigate the effects of cannabis on simulated driving in young as compared to middle-aged drivers. Half of the participants will be occasional users of cannabis and half will be frequent users of cannabis.
Gender: All
Ages: 19 Years - 45 Years
Updated: 2026-03-23
1 state
NCT07434895
Repeated CBD Administration and Cannabis Outcomes
This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.
Gender: All
Ages: 18 Years - 55 Years
Updated: 2026-02-27
1 state
NCT07417059
Sex Hormones Impact on Cannabis Response
The goal of this study is to systematically determine whether the cannabis response in human females is related to SH fluctuations throughout the menstrual cycle.
Gender: FEMALE
Ages: 18 Years - 40 Years
Updated: 2026-02-18
NCT05160688
Changes in Cognition and Psychiatric Disorder Symptoms During Cannabis Abstinence Using a Novel Discordant Twin Design
This study will test whether 42 days of cannabis abstinence, compared to continued cannabis use, is associated with improvements in cognition and psychiatric disorder symptoms. Identical twins, who are concordant on cannabis use, will be experimentally-manipulated to be discordant for 42 days. Each twin, within a twin pair, will be randomly assigned to either the contingency management condition, incentive-based protocol to promote cannabis abstinence, or control condition, no changes in cannabis use requested.
Gender: All
Ages: 31 Years - 47 Years
Updated: 2026-02-12
1 state
NCT05629702
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
ARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, randomised trial to compare the cannabinoid Nabiximols with placebo in patients with recurrent MGMT methylated glioblastoma (GBM) treated with temozolomide (TMZ).
Gender: All
Ages: 16 Years - Any
Updated: 2026-01-30
2 states
NCT05999383
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.
Gender: All
Ages: 21 Years - 65 Years
Updated: 2026-01-07
1 state
NCT06099379
Modulation of THC Effects by CBD: a Dose-ranging Study
The purposes of this study are 1) to determine if CBD modulates THC-induced acute psychoactive effects at different CBD:THC ratios, compared with the control product (0:20, 20:20, 40:20, 80:20, 120:20) and 2) to determine if different doses of CBD modulate other THC induced behavioral effects, compared with the control product and 3)To explore qualitatively whether CBD modulates THC effects by mechanisms that are not detected with standard clinical research tools.
Gender: All
Ages: 21 Years - 49 Years
Updated: 2025-12-22
1 state
NCT05320367
A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users
The purposes of this study are 1) to determine if the administration of different low doses of CBD (5 mg, 20 mg, 50 mg and 100 mg) result in detectable subjective pleasant drug effect compared to placebo and 2) to qualitatively explore whether low dose CBD is associated with effects that are not detected with the available research tools.
Gender: All
Ages: 21 Years - 49 Years
Updated: 2025-12-22
NCT06235632
Responsible Marijuana Sales Practices to Reduce the Risk of Selling to Intoxicated Customers
The new recreational marijuana markets are contributing to polysubstance-impaired driving and other harms, especially when marijuana is used in combination with alcohol, by selling marijuana to obviously-intoxicated customers. In this study, the effectiveness of an intervention to reduce the risk of marijuana sales to obviously-intoxicated customers will be tested in the state-licensed recreational marijuana market in Oregon, one of the first states to ban such sales. The intervention will combine efforts by state regulators to increase deterrence of the state law prohibiting marijuana sales to obviously-intoxicated customers with training of store personnel to recognize signs of intoxication and refuse sales. It will also include testing the rate at which visibly intoxicated customers are refused alcohol at nearby establishments that sell alcohol either on-site or off-site
Gender: All
Ages: 21 Years - Any
Updated: 2025-12-05
1 state
NCT06120855
Study on Regulated Cannabis Sales in Pharmacies
Though regulated cannabis sales are increasing, little is known about the individual health effects of cannabis regulation. Data from countries with a regulated market can be used to test the effect of regulation on the price of cannabis in the illicit market, and to explore its effect on social and health outcomes at the societal level, but strength of evidence for individual health and social outcomes is more limited because it must be aggregated on a state or country level. Data on individual and social outcomes should include baseline measurements before and outcome measurements after regulations changed. In this context, randomized-controlled trials are the least biased source of data on the effects of interventions. The SCRIPT study aims to investigate the individual health and social impact on recreational cannabis users who are allowed to purchase authorized, regulated cannabis from Swiss pharmacies compared to users who buy cannabis on the illicit market. Participants are randomly allocated in one of the two groups and followed-up for 6 months. After 6 months, all participants are allowed to participate in the intervention and the cohort is followed up for another 18 months. The intervention includes various offers: Participants can choose between cannabis sorts and delivery methods, and they are encouraged to shift from smoking cannabis to vaping cannabis-containing e-liquids, vaporizing cannabis blossoms or using oral cannabis. Vaping / vaporizing electronic devices are also recommended. At the same time, pharmacists offer opportunistic smoking cessation and problematic cannabis, alcohol use and further drug use counseling that conforms to motivational interviewing principles. The SCRIPT study adheres to rigorous quality criteria for the production and storage of regulated cannabis products. Only vaping / vaporizing electronic devices which are validated to reduce exposure to toxicants compared to cannabis smoking are recommended.
Gender: All
Ages: 18 Years - Any
Updated: 2025-11-18
NCT04816994
Effect of Cannabis Extract on Acute Radicular Pain and on Analgesic Requirement
Clinical evidence about the effects of cannabis in the management of acute pain is rather scarce, mostly consisting of case report-based opinions on adverse events during or after general anesthesia after smoking cannabis, experimental pain trials in healthy volunteers, and a few clinical trials using different drugs, dosages and routes of administration. It is difficult to draw strong conclusions from the available evidence, that may seem sometimes even contradictory, mainly due -the investigators believe- to the many sources of variability in the study designs (e.g.: heterogeneity of the study samples, underpowered, unblinding, lack of randomization, timing of the therapeutic intervention, different experimental pain models, inclusion of different kind of surgical pain, etc.). Nevertheless, expert's opinion after a critical review of the literature is that cannabis and cannabinoids may have a beneficial role in the management of acute pain, at least for a selected group of patients and through an appropriate therapeutic intervention. Cannabis oil seem to be most suitable to our investigation. The co-administration of tetrahydrocannabinol (THC) with cannabidiol (CBD) may translate into additional therapeutic benefits with an attenuation of adverse effects. And will help treat acute radicular back pain and for renal colic.
Gender: All
Ages: 18 Years - 70 Years
Updated: 2025-10-02
NCT07194018
Use of Cannabis Oil in Fibromyalgia
Recently, medical cannabis has been shown to be effective in chronic pain conditions such as osteoarthritis, neuropathic pain, and other chronic non-cancer pain. A study showed that fibromyalgia patients who use cannabis report significant improvement in pain symptoms and quality of life. Patients reported a 50% reduction in pain, and many also reported improvements in sleep and overall well-being. Further research found that the use of medical cannabis among patients with fibromyalgia led to significant improvements in pain, sleep quality, and overall quality of life. This study emphasized that adverse effects were generally mild and tolerable. Furthermore, the systematic review by Fitz et al. concluded that cannabis may be effective in treating fibromyalgia, with preliminary evidence indicating improvements in pain and sleep disturbances. However, it also highlighted the need for further randomized controlled trials to confirm these findings and determine how the cannabinoid system interacts with the pain pathway. Considering that medical cannabis is effective in treating a variety of symptoms, including pain, cachexia and wasting, sleep disorders, severe or persistent muscle spasms, reduced fatigue in multiple sclerosis, chemotherapy-induced nausea, convulsive disorders, post-traumatic stress disorder, and other conditions in palliative and end-of-life care; with this study, given the premises of the effects of medical cannabis, the aim is to analyze its use also in chronic pain as the main symptom of fibromyalgia syndrome.
Gender: All
Ages: 21 Years - Any
Updated: 2025-09-26
1 state
NCT02407808
Cannabinoids, Learning, and Memory
The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.
Gender: All
Ages: 18 Years - 55 Years
Updated: 2025-06-10
1 state
NCT02811510
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Gender: All
Ages: 18 Years - 55 Years
Updated: 2025-06-10
1 state
NCT02781519
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Gender: All
Ages: 18 Years - 55 Years
Updated: 2025-06-10
1 state
NCT02404688
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
Gender: All
Ages: 21 Years - 55 Years
Updated: 2025-04-15
1 state
NCT02710097
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
Gender: All
Ages: 21 Years - 55 Years
Updated: 2025-04-15
1 state
NCT02709954
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
Gender: All
Ages: 21 Years - 55 Years
Updated: 2025-04-15
1 state
NCT02710331
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
Gender: All
Ages: 21 Years - 55 Years
Updated: 2025-04-09
1 state
NCT06919276
Nicotine and Cannabis Vape Labeling Experiment - Spring 2025
This study assesses how the ways in which nicotine and cannabis vaping devices are labeled impact use susceptibility, anticipated effects, and health harm.
Gender: All
Ages: 11 Years - 19 Years
Updated: 2025-04-09
1 state
NCT06473701
Reducing Breathlessness With Dronabinol in COPD Patients
This clinical trial examines whether Dronabinol, which contains the synthetic psychoactive compound tetrahydrocannabinol (THC), can alleviate severe breathlessness in patients with severe and very severe chronic obstructive pulmonary disease (COPD).
Gender: All
Ages: 18 Years - Any
Updated: 2025-03-28
1 state
NCT05116527
THC Memory & Reward Learning Pilot
Tetrahydrocannabidiol (THC) is the psychoactive chemical in cannabis that makes people high. This study aims to dissect acute impairment of various forms of memory and learning by THC in cannabis compared to placebo. Impairment will be assessed via a short cognitive test battery and then subjects will complete four tasks in the fMRI scanner.
Gender: All
Ages: 18 Years - 55 Years
Updated: 2025-03-17
1 state
NCT04704271
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Gender: All
Ages: 18 Years - 55 Years
Updated: 2025-03-06
1 state